{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:50:40Z","timestamp":1791957040343,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.ajkd.2025.04.020","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:33:06Z","timestamp":1751423586000},"page":"516-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gout Management in Patients With CKD: A Review"],"prefix":"10.1053","volume":"86","author":[{"given":"Rochella A.","family":"Ostrowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ajkd.2025.04.020_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006843","article-title":"Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study","volume":"5","author":"Wang","year":"2015","journal-title":"BMJ Open"},{"issue":"10225","key":"10.1053\/j.ajkd.2025.04.020_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2025.04.020_bib5","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.04.020_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","article-title":"Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010","volume":"42","author":"Juraschek","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1053\/j.ajkd.2025.04.020_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.kint.2024.05.033","article-title":"Controversies and practical management of patients with gout and chronic kidney disease","volume":"106","author":"Johnson","year":"2024","journal-title":"Kidney Int"},{"issue":"17","key":"10.1053\/j.ajkd.2025.04.020_bib8","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice: gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.04.020_bib9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2025.04.020_bib11","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/BOR.0000000000000031","article-title":"Safety profile of anti-gout agents: an update","volume":"26","author":"Stamp","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1053\/j.ajkd.2025.04.020_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2369-12-36","article-title":"Chronic kidney disease in gout in a managed care setting","volume":"12","author":"Fuldeore","year":"2011","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","article-title":"Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study","volume":"8","author":"Francis-Sedlak","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"8","key":"10.1053\/j.ajkd.2025.04.020_bib16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.04.020_bib17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.22767","article-title":"Quality of care for gout in the US needs improvement","volume":"57","author":"Singh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS Trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1053\/j.ajkd.2025.04.020_bib19","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2025.04.020_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-018-1755-0","article-title":"How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose","volume":"20","author":"Stamp","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","article-title":"Up-titration of allopurinol in patients with gout","volume":"44","author":"Jennings","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1053\/j.ajkd.2025.04.020_bib22","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/ard-2023-224731","article-title":"Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial","volume":"82","author":"Stamp","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2025.04.020_bib24","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1053\/j.ajkd.2025.04.020_bib25","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1053\/j.ajkd.2025.04.020_bib26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B\u221758:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1053\/j.ajkd.2025.04.020_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B\u22175801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdermsci.2013.04.013","article-title":"HLA-B\u221758:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population","volume":"71","author":"Niihara","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"5","key":"10.1053\/j.ajkd.2025.04.020_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Adverse Drug Reaction Research Group in Korea. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"10.1053\/j.ajkd.2025.04.020_bib30","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2025.04.020_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12193","article-title":"HLA-A\u221724:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B\u221758:01 carriers in a Korean population; a multicenter cross-sectional case-control study","volume":"12","author":"Kim","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1053\/j.ajkd.2025.04.020_bib33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B\u22175801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 9","key":"10.1053\/j.ajkd.2025.04.020_bib34","article-title":"HLA-B\u221758:01 genotype and the risk of allopurinol-associated severe cutaneous adverse reactions in a predominately Black or African American population with advanced chronic kidney disease [ACR\/ARHP abstract 1292]","volume":"70","author":"Ford","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","article-title":"Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States","volume":"46","author":"Lu","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1053\/j.ajkd.2025.04.020_bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1053\/j.ajkd.2025.04.020_bib37","first-page":"1209","article-title":"Febuxostat in the management of hyperuricemia and chronic gout: a review","volume":"4","author":"Hu","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"23","key":"10.1053\/j.ajkd.2025.04.020_bib38","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2025.04.020_bib39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ajkd.2025.04.020_bib40","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1053\/j.ajkd.2025.04.020_bib41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2024.04.017","article-title":"Efficacy and safety of allopurinol and febuxostat in patients with gout and CKD: subgroup analysis of the STOP Gout Trial","volume":"84","author":"Helget","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.04.020_bib42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2174\/1381612825666190408122557","article-title":"Hyperuricemia and cardiovascular disease","volume":"25","author":"Zhang","year":"2019","journal-title":"Curr Pharm Des"},{"issue":"13","key":"10.1053\/j.ajkd.2025.04.020_bib43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2025.04.020_bib44","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/art.42160","article-title":"Evaluation of the relationship between serum urate levels, clinical manifestations of gout, and death from cardiovascular causes in patients receiving febuxostat or allopurinol in an outcomes trial","volume":"74","author":"Saag","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.ajkd.2025.04.020_bib45","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.ajkd.2025.04.020_bib46","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/clc.23643","article-title":"Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis","volume":"44","author":"Gao","year":"2021","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.04.020_bib47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2015.07.011","article-title":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol: a retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","volume":"83","author":"Bardin","year":"2016","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2025.04.020_bib49","series-title":"Two gout drugs removed from market","year":"2019"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","volume":"51","author":"Keenan","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.04.020_bib54","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.ajkd.2025.04.020_bib55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/annrheumdis-2020-eular.4642","article-title":"THU0410. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout","volume":"79","author":"Rainey","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.04.020_bib57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1053\/j.ajkd.2025.04.020_bib58","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-Reduced Trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1053\/j.ajkd.2025.04.020_bib59","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.04.020_bib60","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2025.04.020_bib61","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221083509","article-title":"Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2025.04.020_bib62","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.13170","article-title":"Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin","volume":"20","author":"Ouchi","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ajkd.2025.04.020_bib63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2025.04.020_bib64","series-title":"UpToDate","article-title":"Gout: Treatment of Flares","author":"Gaffo","year":"2024"},{"issue":"1","key":"10.1053\/j.ajkd.2025.04.020_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"10.1053\/j.ajkd.2025.04.020_bib66","series-title":"Deerfield, IL: Takeda Pharmaceuticals America","year":"2012"},{"issue":"3","key":"10.1053\/j.ajkd.2025.04.020_bib67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","article-title":"Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management","volume":"46","author":"Hansten","year":"2023","journal-title":"Drug Saf"},{"key":"10.1053\/j.ajkd.2025.04.020_bib68","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2025.04.020_bib69","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1053\/j.ajkd.2025.04.020_bib71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jbspin.2018.03.015","article-title":"Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study","volume":"85","author":"Loustau","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1053\/j.ajkd.2025.04.020_bib72","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1053\/j.ajkd.2025.04.020_bib73","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/00007890-199606150-00023","article-title":"Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation","volume":"61","author":"Cummins","year":"1996","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.ajkd.2025.04.020_bib74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM198908033210504","article-title":"Cyclosporine-induced hyperuricemia and gout","volume":"321","author":"Lin","year":"1989","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.04.020_bib75","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1399-3046.2006.00556.x","article-title":"Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children","volume":"10","author":"Tumgor","year":"2006","journal-title":"Pediatr Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2025.04.020_bib76","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1016\/j.transproceed.2005.08.042","article-title":"Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients","volume":"37","author":"Kanbay","year":"2005","journal-title":"Transplant Proc"},{"issue":"suppl 10","key":"10.1053\/j.ajkd.2025.04.020_bib77","article-title":"Efficacy of high dose versus moderate dose prednisone in the treatment of acute gout [ACR\/ARHP abstract 1112]","volume":"69","author":"Ostrowski","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625009242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625009242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:49:43Z","timestamp":1758577783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625009242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0272638625009242"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.04.020","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gout Management in Patients With CKD: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}]}}